MASUI
CRSP icon

MIRAE ASSET SECURITIES (USA) INC.’s CRISPR Therapeutics CRSP Stock Holding History

MIRAE ASSET SECURITIES (USA) INC.’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,534
Closed -$407K – 161
2024
Q2 		$407K Buy
+7,534
New +$436K 0.02% 186

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

MIRAE ASSET SECURITIES (USA) INC.'s CRSP Position: Q3 2024 in Review

MIRAE ASSET SECURITIES (USA) INC. sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 7,534 shares — an estimated $407K sold.

MIRAE ASSET SECURITIES (USA) INC. first reported a position in CRSP in Q2 2024 and held it in 1 quarter. The position peaked at $407K in Q2 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • MIRAE ASSET SECURITIES (USA) INC. reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • MIRAE ASSET SECURITIES (USA) INC. sold 7,534 CRISPR Therapeutics shares in Q3 2024, an estimated $407K.
  • MIRAE ASSET SECURITIES (USA) INC. first reported a position in CRISPR Therapeutics in Q2 2024 and held it in 1 quarter.
  • MIRAE ASSET SECURITIES (USA) INC.'s CRISPR Therapeutics position peaked at $407K in Q2 2024.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on MIRAE ASSET SECURITIES (USA) INC.'s 13F filing for Q3 2024, filed 6 Nov 2024.